Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats

2012 ◽  
Vol 691 (1-3) ◽  
pp. 297-306 ◽  
Author(s):  
Wataru Inaba ◽  
Hiroki Mizukami ◽  
Kosuke Kamata ◽  
Kazunori Takahashi ◽  
Kentaro Tsuboi ◽  
...  
Keyword(s):  
Endocrine Cells ◽  
Dipeptidyl Peptidase ◽  
Term Treatment ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Long Term Treatment ◽  
Type 2 Diabetic

Abstract 15107: Long-Term Treatment With Sitagliptin Provides Multiple Ultrasonic-Evaluated Antiatherosclerotic Effects Independent of Diabetic Improvement for Type-2 Diabetics

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Tatsuaki Murakami ◽  
Sumio Mizuno
Keyword(s):  
Intima Media Thickness ◽  
Term Treatment ◽  
Dipeptidyl Peptidase 4 ◽  
Type 2 Dm ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Type 2 Diabetics ◽  
Long Term Treatment ◽  
High Resolution Ultrasonography

Introduction: Diabetes mellitus (DM) is thought to be highly involved in complex atherothrombogenic processes, but the long-term antiatherosclerotic therapies in patients with type-2 DM have not been established. Hypothesis: Therefore we assessed hypothesis long-term treatment sitagliptin, a dipeptidyl peptidase-4 inhibitor recently developed antidiabetic agent, chronically inhibits atherosclerotic progression in patients with type-2 DM. Methods: Thirty-two type-2 diabetic patients with stable coronary artery disease were randomized to group-S where they received sitagliptin (50mg/day), or to group-C where they received enhanced antidiabetic therapy without a dipeptidyl peptidase-4 inhibitor for 2 years. We quantified flow-mediated endothelium-dependent dilation of right brachial artery after 5 minutes forearm occlusion (BFMD), and intima-media thickness of brachial artery (BIMT) using high-resolution ultrasonography. We also quantified intima-media thickness of common carotid artery (CIMT) using high-resolution ultrasonography. Changes in BFMD, BIMT, and CIMT were compared between the two study groups. Results: Group-S (n=16) manifested good compliance to the long-term treatment and improvements in diabetic and lipid variables represented by HbA1c and LDL after long-term medication of sitagliptin, while there were no improvements in group-C. BFMD (%) improved after medication in group-S (from 3.9±1.8 to 6.4±2.6, p<0.01) and BIMT (mm) decreased in group-SG (from 0.35±0.10 to 0.32±0.11, p=0.03), while both remained unchanged in group-C (BFMD; from 4.1±2.0 to 4.1±1.9, p=0.88, BIMT; from 0.34±0.13 to 0.35±0.12, p=0.54). CIMT (mm) did not increase in group-S (from 1.10±0.35 to 1.08±0.39, p=0.16) but increased in group-C (from 1.09±0.46mm to 1.16±0.47mm, p<0.01). Changes of BFMD or BIMT in group-S did not correlate to those of HbA1c (BFMD: r=0.17, p=0.79, BIMT: r=0.11, p=0.85). Conclusions: This study suggests that long-term treatment of sitagliptin safely improves arterial function and inhibits progression of wall thickness independent of reversal for diabetic status, which may have beneficial potentials for long-term management of atherosclerosis in type-2 diabetics.

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

Metabolism ◽  
2013 ◽  
Vol 62 (3) ◽  
pp. 347-351 ◽  
Author(s):  
Noriko Satoh-Asahara ◽  
Yousuke Sasaki ◽  
Hiromichi Wada ◽  
Mayu Tochiya ◽  
Azusa Iguchi ◽  
...  
Keyword(s):  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Anti Inflammatory ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document